No profile data available.
Akari Therapeutics, Plc (AKTX) is a healthcare company in the additional cancer treatment drugs industry, based in Tampa, United States, with about 5 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$17.30 million. Its market capitalization was $20.04 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.
Akari Therapeutics reported $0 in revenue for fiscal year 2025.
$20.04 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Intensity Therapeutics, Inc. (INTS), Immutep Limited (IMMP), Shuttle Pharmaceuticals Holdings, Inc. (SHPH), Curis, Inc. (CRIS).